This is a retrospective, non-interventional study designed to describe the characteristics, clinical outcomes, treatment patterns, and productivity loss in Finnish treatment-naïve study subjects with relapsing-remitting multiple sclerosis (RRMS) who initiated treatment with either ofatumumab or selected oral moderate-efficacy disease modifying therapies (meDMTs; dimethyl fumarate, diroximel fumarate, and teriflunomide) . The study will use data from multiple national registries.
